Unique ID issued by UMIN | UMIN000008380 |
---|---|
Receipt number | R000009852 |
Scientific Title | A clinical study of cancer peptides vaccine therapy in the patients who have recieved surgical resection and had no residual tumor for head and neck cancer |
Date of disclosure of the study information | 2012/07/08 |
Last modified on | 2012/07/08 21:38:13 |
A clinical study of cancer peptides vaccine therapy in the patients who have recieved surgical resection and had no residual tumor for head and neck cancer
A clinical study of adjuvant peptides vaccine therapy after surgical resection of head and neck cancer
A clinical study of cancer peptides vaccine therapy in the patients who have recieved surgical resection and had no residual tumor for head and neck cancer
A clinical study of adjuvant peptides vaccine therapy after surgical resection of head and neck cancer
Japan |
head and neck cancer
Dental medicine |
Malignancy
YES
Conformation of safty and efficacy of adjuvant peptides vaccine therapy for head and neck cancer using peptides in the patients who have recieved surgical resection and had no tumor.
Safety,Efficacy
Pragmatic
Phase I,II
safty
immunological response and clinical efficacy
Interventional
Parallel
Non-randomized
Open -but assessor(s) are blinded
No treatment
2
Treatment
Vaccine |
peptides vaccine therapy using URLC10, CDCA1, and KOC1-targeted peptides in the patients who have recieved surgical resection and had no tumor of head and neck cancer
no peptides vaccine therapy
16 | years-old | <= |
85 | years-old | >= |
Male and Female
1. Patients who have no treatment against oral cancer.
2. Performance status of patients are 0-2.
3. more than 20, less than 85 years of age.
4. At least 4 weeks past after the patient has received last treatment.
5. Has adequate organ function as difined by following criteria.
1) WBC count more than 2000/mm3, less than 25000/mm3
2) Plt count more than 50000/mm3
3) AST and ALT less than 150IU/L
4) T.Bil less than 3.0mg/dl
5) Cr less than 3.0mg/dl
6) Patients who have HLA-A*2402.
7) All patients gave written informed consent.
1. Pregnancy or lactation.
2. Patients who are treated with steroid or immunotherapy during clinical trial.
3. Patients have uncontrollable associated cancer.
4. Patients who are not agree.
5. Patients who are inappropriate.
50
1st name | |
Middle name | |
Last name | Masanori Shinohara |
Graduated school of medicine Kumamoto University
Department of Oral and Maxillofacial surgery
1-1-1 Honjo, Kumamoto city, Kumamoto 860-8556, Japan
096-373-5288
1st name | |
Middle name | |
Last name | Yoshihiro Yoshitake |
Graduated school of medicine Kumamoto University
Department of Oral and Maxillofacial surgery
1-1-1 Honjo, Kumamoto city, Kumamoto 860-8556, Japan
096-373-5288
Department of Oral and Maxillofacial surgery, Graduated school of medicine Kumamoto University
Department of Oral and Maxillofacial surgery, Graduated school of medicine Kumamoto University
Self funding
NO
2012 | Year | 07 | Month | 08 | Day |
Unpublished
Open public recruiting
2010 | Year | 06 | Month | 11 | Day |
2010 | Year | 10 | Month | 01 | Day |
2012 | Year | 07 | Month | 08 | Day |
2012 | Year | 07 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009852
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |